Chiesi USA donates more than $800,000 in 2020
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2021
Chiesi USA Announces Key Promotions to Business Unit Leads
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
Chiesi USA Appoints Jon Zwinski as General Manager and Chief Executive Officer
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Chiesi USA, Inc. Supports March of Dimes Eastern North Carolina in Observance of Prematurity Awareness Month
Chiesi USA, Inc. Earns Fourth Consecutive Corporate Philanthropy Award by Triangle Business Journal
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
Chiesi Global Rare Diseases Launches “Rethink Fabry” Campaign to Bring Important Information to Fabry Disease Community and Support Patients and Caregivers
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the ProposedTreatment of Fabry Disease
Chiesi USA, Inc. Earns 2020 Life Sciences Award by Triangle Business Journal
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets
Chiesi Global Rare Diseases Recognizes Fabry Disease Awareness Month and Launches “Fabry Focus on Health” Educational Series to Support Patients and Caregivers During COVID-19 Pandemic
Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic
Chiesi USA certified as a Great Place to Work® in 2019
Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020
Chiesi in the Community donates nearly $1 million in 2019
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2020
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
Chiesi and Durham Bulls Partnership Culminates in $15,000 to Triangle Nonprofits
Chiesi Group confirms positive trend to date for 2019
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
Triangle Business Journal Recognizes Chiesi USA, Inc. With Third Consecutive Corporate Philanthropy Award
Paolo Chiesi is Appointed Honorary Doctor at Karolinska Institutet
Chiesi Named Signature Sponsor of the Triangle March for Babies Walk & 5K Run
Chiesi and Durham Bulls Partnership Steps up to Bat for Local Charities
Chiesi USA Promotes Medical Affairs Head to Support Continued Corporate Growth
Chiesi USA, Inc. Moves to New Headquarters in Regency Woods II
Chiesi Joins National Organization for Rare Disorders (NORD)® Corporate Council
Chiesi USA, Inc. Receives Top Employer in the US Certification for 2019
Chiesi in the Community Donates approximately $850,000 in 2018
Chiesi USA Attains Public Benefit Corporation Status, Pledges to Advance Positive Community Impact
Chiesi Salutes Neonatal Intensive Care Unit Staff in Honor of Prematurity Awareness Month®
Chiesi Salutes Nurses Surrounding Neonatal Nurses Day 2018
Chiesi Partnership with Durham Bulls Closes Season with $15,000 to Area Nonprofits
Chiesi USA, Inc. Named a Best Place to Work
Chiesi Foundation Onlus Issues 2018 Call for Scientific Research Proposals
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)